PCDH10 was already reported to be inactivated by promoter methylation in various types of cancer, including non-small cell lung cancer [23], gastric cancer [24], colorectal cancer [25], nasopharyngeal, esophageal [17], endometrioid endometrial carcinoma [26, 27], bladder cancer [28], cervical cancer [29], suggesting that it plays an oncosuppressor role in those tumors. This evidence concerns the gene PCDH10 and urinary bladder carcinoma.